Core Viewpoint - The investment opportunities in the pharmaceutical industry for 2026 are highlighted, particularly in innovative medical devices, innovative drugs, and high-growth CXO and upstream life sciences companies [1] Group 1: Investment Opportunities - Innovative medical devices are identified as a focus area, contingent on performance alignment [1] - After a correction in innovative drugs, certain high-quality targets are recommended for attention [1] - High-growth CXO and upstream life sciences companies are also considered worthy of attention if they can maintain robust business growth [1] Group 2: Market Conditions - The pharmaceutical sector has been at a low point since peaking in 2021, presenting current investment opportunities [1] - Institutional investors may reallocate resources when the fundamentals of pharmaceutical companies improve and performance aligns [1] Group 3: Stock Selection Strategy - The company aims to identify and predict significant turning points in the lifecycle of industries and companies [1] - The strategy involves early market positioning to capture excess returns as industry and company values become recognized, leading to simultaneous performance and valuation increases [1] - A preference for innovative drug industry chains (CXO, upstream life sciences) as a high-probability offensive base, while positioning medical devices as a defensive allocation [1]

Investment Rating - The investment rating for the biopharmaceutical industry is "Outperform the Market" (maintained) [2] Core Insights - The biopharmaceutical industry in A-shares has shown marginal improvement in revenue and profit performance in Q3 2025, with a continued high prosperity in innovative drugs and the industry chain [6][7] - The innovative drug sector has demonstrated robust growth, with a revenue increase of 21.41% year-on-year in the first three quarters of 2025, while the CXO sector also showed significant growth [6][10] - There is a focus on undervalued turnaround targets in the medical device and pharmacy sectors, which have shown signs of stabilization and recovery [6][20] Summary by Sections Financial Summary - In the first three quarters of 2025, A-share pharmaceutical companies achieved a total revenue of 17,480.2 billion yuan, a year-on-year decrease of 1.22%, and a net profit of 1,355.8 billion yuan, down 1.00% year-on-year [6][7] - The innovative drug sector generated revenue of 485.6 billion yuan (+21.41%) and a net profit of -4.6 billion yuan, significantly reducing losses [6][10] - The CXO sector reported revenue of 698.7 billion yuan (+11.66%) and a net profit of 163.9 billion yuan (+56.78%) [6][15] Innovative Drug Sector - The innovative drug sector's revenue for Q3 2025 reached 191.7 billion yuan (+50.66%), with a net profit of 13.1 billion yuan (+155.49%) [10] - The growth in revenue is attributed to the rapid commercialization of innovative drug products and milestone payments from product licensing [10][11] CXO Sector - The CXO sector's revenue for Q3 2025 was 247.5 billion yuan (+10.03%), with a net profit of 51.1 billion yuan (+47.69%) [15] - The sector continues to show mid-to-high-speed growth, although there is some internal differentiation among companies [15] Medical Device Sector - The medical device sector reported revenue of 1,776.8 billion yuan (-2.26%) and a net profit of 265.9 billion yuan (-14.05%) in the first three quarters of 2025 [20] - The sector is expected to recover gradually, with recommendations to focus on leading companies benefiting from domestic demand and international expansion [20] Traditional Chinese Medicine Sector - The traditional Chinese medicine sector achieved revenue of 2,548.7 billion yuan (-3.58%) and a net profit of 302.6 billion yuan (-0.85%) in the first three quarters of 2025 [18] - The sector is stabilizing, with ongoing risks from national procurement policies [18] Life Sciences Upstream - The life sciences upstream sector reported revenue of 96.6 billion yuan (+7.96%) and a net profit of 8.6 billion yuan (+32.08%) in the first three quarters of 2025 [24] - The sector is expected to see improvements in demand as inventory depletion phases out and companies increase R&D investments [25]

Company Summary - Haier Biomedical (688139.SH) reported a revenue of 566 million yuan for Q3 2025, representing a year-on-year growth of 1.24% and a quarter-on-quarter increase of 11.68% [1] - The net profit attributable to shareholders reached 55.65 million yuan, with a significant quarter-on-quarter increase in the net profit excluding non-recurring items [1] Industry Summary - The life sciences upstream industry has entered a new phase of valuation recovery and industrial upgrading after a decade of development [1] - Current sector valuations remain low, supported by three key factors: supply clearing, demand recovery, and accelerated domestic substitution [1]

Core Viewpoint - Haier Biomedical has shown significant performance recovery in Q3 2025, driven by strong revenue growth and improved profitability, indicating a positive trend in the life sciences and medical device sectors as they transition towards international expansion and technological innovation [1][2]. Group 1: Financial Performance - In Q3 2025, Haier Biomedical achieved a revenue of 566 million yuan, representing a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68% [1]. - The net profit attributable to shareholders reached 55.65 million yuan, with a quarter-on-quarter growth exceeding 70% [1]. - The non-recurring net profit was 49.99 million yuan, showing a quarter-on-quarter increase of over 100% [1]. Group 2: Industry Trends - The life sciences sector is entering a new phase of valuation recovery and industrial upgrading after a decade of development, supported by supply clearing, demand recovery, and accelerated domestic substitution [2]. - Haier Biomedical's performance recovery is attributed to revenue growth, business structure upgrades, and enhanced product competitiveness [2]. Group 3: Business Segments - The recovery in Q3 is supported by four key industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, which have begun to show stable performance [3]. - New industries, particularly smart medication and blood technology, have demonstrated significant growth, contributing to approximately 48% of total revenue [3]. - The smart medication segment has established itself among the top three in the automated medication market by addressing hospital drug management challenges [3]. Group 4: Market Position and Innovation - The low-temperature storage segment continues to maintain a leading market share in China, with steady growth in revenue [4]. - Haier Biomedical's commitment to technological innovation is evident in its AI integration and the establishment of a multi-layered AI foundation, enhancing its product offerings and market responsiveness [5][6]. - The company reported a 20.18% year-on-year increase in overseas market revenue, reaching 634 million yuan, with successful localization strategies implemented in 18 countries [6].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the life sciences upstream sector [6]. Core Insights - The life sciences upstream sector is experiencing simultaneous domestic substitution and accelerated international expansion, with significant room for improvement in the localization rates of research reagents, consumables, and high-end scientific instruments [1][22]. - The demand side is improving due to favorable trends in innovative drug development and supportive national policies, with domestic innovative drug companies' overseas business development (BD) transactions expected to exceed $100 billion in 2025, nearly doubling from 2024 [2][25]. - The supply side is also gradually improving, with domestic life sciences companies achieving technological breakthroughs and expanding their business pipelines through both organic growth and acquisitions [2][29]. - Key companies are showing signs of performance improvement, with notable growth in revenue and net profit for firms like Baipusais and Aopumai [2][34]. Summary by Sections 1. Life Sciences Upstream Overview - The life sciences upstream includes research reagents, experimental consumables, instruments, and comprehensive services, playing a crucial role in various applications such as antibody drugs and gene therapy [9][10]. 1.1 Domestic Substitution and International Expansion - The localization rates for research reagents are around 10%, with high-end scientific instruments having an import rate of approximately 70.6% [22][23]. 1.2 Demand Side Improvement - The innovative drug sector is witnessing a recovery, with significant increases in overseas BD transactions, indicating a robust demand for life sciences products [25][27]. 1.3 Supply Side Enhancements - Domestic companies are making technological advancements, with key players like Aopumai and Baipusais expanding their product lines and market presence through acquisitions and internal development [29][30]. 1.4 Company Performance Trends - Companies such as Baipusais and Aopumai have reported substantial improvements in their financial performance, with Baipusais showing a 31% year-on-year revenue growth and Aopumai achieving a remarkable 402% increase in net profit [34]. 2. Recommended Stocks - Suggested stocks to watch include Baipusais, Aopumai, Aladdin, and others in the research reagent and scientific instrument sectors [2].

Core Insights - The report from Zhejiang Securities indicates that the recovery of the upstream life sciences sector in the first half of the year is primarily driven by a stable improvement in the supply-demand balance, with expectations for further profit elasticity and rapid valuation digestion in the fourth quarter and next year [1][2] - The overseas demand recovery has been more pronounced compared to domestic demand, but there is a significant acceleration in domestic business growth for many companies, with improved accounts receivable turnover rates for reagents and consumables [1] - The firm is optimistic about the performance of upstream companies benefiting from a combination of commercial project expansion, accelerated domestic import substitution, and international market expansion [1] Industry Trends - Despite some stocks in the sector returning to their 2022-2023 valuation levels, there is still potential for upward movement based on the recovery of fundamentals and investment opportunities [2] - The industry is entering a new phase characterized by breakthroughs in biotechnology, local innovation, favorable liquidity conditions (with the Federal Reserve's interest rate cuts), and a recovery in the capital cycle, which is expected to enhance the valuation of the innovation chain [2] - The positive trends in the domestic new drug research and development environment, along with successful commercialization pathways, are anticipated to sustain the acceleration of demand for chromatography fillers, culture media, and synthetic reagents [1]

Summary of the Conference Call on China's Healthcare Industry Industry Overview - The conference call focused on the **China Healthcare Industry**, specifically the **life sciences sector** [1][6]. - A strong wave of **innovation drug asset licensing** and a new round of **interest rate cuts** are revitalizing the Chinese life sciences industry after years of consolidation [1]. Key Companies Covered - **Acrobiosystems** (百普赛斯) - Rated **Overweight** with a target price of **RMB 102.50** [11][12]. - **Tofflon** (东富龙) - Rated **Equal-weight** with a target price of **RMB 16.77** [13][15]. Core Insights - The current upcycle in the industry is driven by the **globalization of early-stage innovative drug assets**, leading to increased demand for early drug discovery and development services [2]. - Preference is given to companies that directly serve early drug development needs over those focused on late-stage commercial production, which face challenges such as limited overseas demand and prolonged equipment replacement cycles [2]. - **Acrobiosystems** is considered undervalued due to its unique operational platform, focus on industrial clients, and strong growth potential driven by innovation drug development [2][11]. - **Tofflon** is expected to maintain a reasonable valuation despite moderate terminal market demand and a complex domestic replacement process [13][14]. Financial Metrics - **Acrobiosystems**: - Expected **CAGR** of **55%** from 2024 to 2027, with a current **P/E** ratio of **34x** for 2026 [11][12]. - Anticipated **net profit margin** expansion due to strong sales growth and operational leverage [11]. - **Tofflon**: - Expected **CAGR** of **42%** from 2024 to 2027, with a current **P/E** ratio of **22x** for 2026 [14][15]. - Revenue projections show a gradual increase from **RMB 5.01 billion** in 2024 to **RMB 6.24 billion** in 2027 [15]. Risks Identified - **Downside Risks**: - Geopolitical uncertainties, unexpected regulatory changes, price competition, and delays in domestic replacement processes [3]. - **Upside Potential**: - Accelerated domestic replacement processes, increased demand from a growing drug pipeline, and easing geopolitical concerns could enhance valuations [3]. Conclusion - The Chinese life sciences sector is poised for growth driven by innovation and favorable financing conditions, with specific companies like **Acrobiosystems** and **Tofflon** positioned to capitalize on these trends. The analysis suggests a favorable investment environment, albeit with certain risks that need to be monitored closely [1][2][3].

Investment Rating - The report assigns a "Buy" rating to Thermo Fisher, while other companies such as Danaher, Samsung Bio, and Lonza remain unrated [2]. Core Insights - The report highlights that the impact of tariffs on the life sciences upstream sector is less than expected, leading to an overall upward revision of performance guidance for 2025 by most companies [4][29]. - Clinical CRO orders have unexpectedly increased, driven by strong biotech client demand, although the sustainability of this trend remains uncertain [4][31]. - The revenue recovery is outpacing profit recovery, with cost control pressures increasing due to external macroeconomic challenges [6][14]. Summary by Sections Performance Analysis - In 1H25, the performance of overseas CXO and life sciences upstream companies remained under pressure, but a sequential improvement was observed in 2Q25, with 7 out of 10 tracked companies showing revenue growth compared to 1Q25 [6][31]. - The median and average revenue growth rates for 2Q25 were +4.3% and +7.1%, respectively, compared to +0.2% and +6.0% in 1Q25, primarily driven by clinical CRO companies [6][8]. Tariff Impact - The impact of tariffs on sales of instruments and equipment for drug development and production was reported to be less than anticipated, with management from major life sciences companies indicating a more favorable outlook [29][30]. - Companies like Thermo Fisher and Danaher have adjusted their performance guidance upwards, reflecting a more optimistic view on tariff impacts [29][30]. Demand Trends - The C(D)MO sector continues to see strong commercial production demand, while life sciences upstream companies benefit from a recovery in consumable demand as clients complete inventory destocking [31][32]. - Clinical CRO demand has been bolstered by unexpected growth from biotech clients, although the sustainability of this demand is still in question [33][34]. Financial Metrics - The average gross margin for heavy asset companies decreased from 50.2% in 2021 to 45.7% in 2024, but showed signs of recovery in 2Q25 [15]. - The report notes that capital expenditures are expected to reverse the declining trend observed in 2023-24, potentially increasing future depreciation pressures [17]. Market Reactions - Following the release of 2Q25 results, stock prices for most overseas CXO and life sciences companies reacted positively, particularly for clinical CROs, which saw significant price increases due to better-than-expected performance [24][25].

Group 1 - Goldman Sachs expects the Federal Reserve to cut interest rates in September, reflecting early signs of milder inflation related to tariffs and emerging deflationary forces [1] - Goldman Sachs raises its S&P 500 index target for the next 12 months by 11%, citing earlier and deeper monetary easing by the Fed and strong fundamentals of large-cap stocks [1] - The S&P 500 index's expected returns for 3 months, 6 months, and 12 months have been adjusted to +3%, +6%, and +11% respectively, with new target levels set at 6,400, 6,600, and 6,900 points [1] Group 2 - Morgan Stanley indicates that U.S. trade negotiations are moving towards a tactical escalation, with potential increases in tariffs affecting Asian economies [2] - Mizuho Securities notes that OPEC+ plans to increase production by 548,000 barrels per day, reflecting Saudi confidence in market demand rather than an intention to capture market share [3] - Nomura Securities suggests that clearer trade tariffs could help the market eventually rise, as new agreements may reduce uncertainty [5] Group 3 - Bank of America reports that improved Canada-U.S. relations and reduced tariff tensions are likely to benefit the Canadian banking sector [4] - OCBC Bank highlights that despite recent cooling measures in Singapore's real estate market, there remains potential for price and transaction volume increases [7] - Goldman Sachs predicts that the Reserve Bank of Australia will cut rates by 25 basis points in July, with a terminal rate potentially dropping to 3.10% [8] Group 4 - Westpac Bank expects the Reserve Bank of New Zealand to maintain its cash rate in July, leaving the market to interpret future rate changes [9] - CICC notes that the Hong Kong stock market is entering a new era driven by active trading and structural changes in asset and funding dynamics [7] - Huatai Securities anticipates a turning point for IDC due to growing domestic and international demand for intelligent computing centers [8] Group 5 - Galaxy Securities identifies new investment opportunities in the upstream life sciences sector, driven by recovery in revenue growth and domestic substitution trends [9]

Market Overview - A-shares experienced a rebound in early trading, with the Shanghai Composite Index approaching the 3500-point mark, and the ChiNext Index rising over 2% to lead the three major indices [1] - As of the midday close, the Shanghai Composite Index was at 3493.16 points, up 0.58%, with a trading volume of 340.4 billion; the Shenzhen Component Index was at 10568.25 points, up 1.27%, with a trading volume of 532.4 billion; the ChiNext Index was at 2178.22 points, up 2.25%, with a trading volume of 264 billion [1] Sector Performance - The photovoltaic, PCB, gaming, and CPO sectors saw significant gains, while insurance, banking, electricity, and controllable nuclear fusion sectors experienced declines [1] - Computing hardware stocks collectively strengthened, with PCB stocks leading the gains, and over ten stocks, including Industrial Fulian, hitting the daily limit [2] - Consumer electronics concept stocks were active, with Furong Technology reaching the daily limit [2] Institutional Insights - Fuyuan Fund suggests that major indices are nearing previous highs, recommending a cautious approach while focusing on technology sectors that have been in adjustment, such as AI computing, applications, and robotics [4] - Galaxy Securities highlights the life sciences upstream sector, which includes instruments, consumables, raw materials, and services, noting its high barriers and cyclical nature. Despite a downturn post-pandemic, leading companies are expanding and accelerating overseas layouts [4] - The life sciences upstream sector is currently at historical low price levels, but a revenue growth turning point is anticipated, with major companies expected to see a 10.75% year-on-year revenue increase in 2024 and a 9.5% increase in Q1 2025, driven by stable investment and domestic substitution trends [4] News Highlights - ByteDance denied reports that it agreed to sell TikTok's U.S. operations to a consortium led by Oracle, stating that the information is inaccurate [5] - The Hong Kong Securities and Futures Commission announced the expansion of the Southbound Trading participant scope to include brokerages, insurance companies, wealth management, and asset management firms [6] - 33 construction companies jointly issued a "anti-involution" initiative to promote industry transformation and fair competition, emphasizing technological innovation and sustainable value creation [7]